| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 83 | / | 2022 | ||||||||
| Date of issue: | 2022-10-26 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Merger of the subsidiary "Biopharm-engineering" AD into "Sopharma" AD | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Biopharm-Engineering" AD, UIC: 119055339 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 97.15% in the capital of the company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2022_Biopharm_merger_EN_espi.pdf | Merger of the subsidiary "Biopharm-engineering" AD into "Sopharma" AD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2022-10-26 | Ognian Donev | Executive director | |||
SFA_2022_Biopharm_merger_EN_espi.pdf
